ArticleNature chemical biology2025
ALFA nanobody-guided endogenous labeling.
Article in Nature chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Single-Molecule Imaging of Endogenous RNA Using a Miniaturized and Circularly Permuted CRISPR-Cas13 Degron-Masking System CDegSR.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Design and validation of a ribosome display library for synthetic nanobody selection.Advanced biotechnology · 2026Article
- High-fidelity single-frame computational super-resolution using signal-preserving denoising-enabled deconvolution.Nature communications · 2026Article
- Programmable nanobody circuits for cell selection.bioRxiv : the preprint server for biology · 2026Article
- Af-CUT&Tag: a sensitive and antibody-free chromatin profiling method using genetically encoded tags and high-affinity binders fused to Tn5.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Small peptide tags offer advantages as their compact size reduces target protein interference, making them valuable for labeling endogenous proteins. However, the lack of inherent fluorescence poses challenges for post-genome knockin monoclonal clone screening. Here we report an adaptable approach leveraging antigen-stabilizing fluorescent protein-fused nanobodies (Nbs) to selectively illuminate cells with successful ALFA tag knockins, streamlining high-throughput cell screening using fluorescence-activated cell sorting. Through targeted mutations and screening of ALFA Nbs (NbALFA), the fluorescently labeled Nb can be selectively degraded in the absence of the ALFA peptide. Conversely, successful insertion of the ALFA peptide into the genome results in a substantial increase in the fluorescence intensity of the Nb. This technique, termed ALFA Nb-guided endogenous labeling (ANGEL), enables a wide array of versatile applications within the native cellular environment. These applications include precise protein labeling and signal amplification through the tandem arrangement of ALFA tags, dynamic monitoring of protein behavior, initiation of protein degradation processes and analysis of protein interactome.
Indexed as
Identifiers
40883491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.